There are currently many approved vaccines worldwide for the prevention of COVID-19, with many individuals being at higher risk of contracting the virus than others. Prof. Renslow Sherer (The University of Chicago Medicine, Chicago, IL, USA) discusses the factors increasing the risk of contracting COVID-19, what we have learned about long-term efficacy of mRNA vaccines, and the evidence in favour of a 4th vaccination in older adults.
View more content from Prof. Renslow Sherer: Interventions to reduce transmission of COVID-19
The presentation entitled: ‘COVID-19 Update Part 1: Prevention’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.
- What factors increase the risk of severe COVID-19? (0:05)
- What have we learned about the long-term efficacy of mRNA vaccines, and what is the evidence in favour of a 4th vaccination in older adults? (2:19)
Disclosures: Renslow Sherer receives grant/research support from Gilead Sciences
Support: Interview and filming supported by Touch Medical Media. Interview conducted
Access further resources from Prof. Renslow Sherer: Lessons in Resilience – What HIV Teaches Us About COVID-19
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]